30.25 USD
▼-1.43-4.51%
盘后 33.75 0.00%
2026-09-15
市值
$1.18B
市盈率
—
EPS
-2.38
股息率
—
52 周区间
3.59 – 37.48
成交量
420.38K
Beta
1.16
目标价
38.38
52W 低 3.5952W 高 37.48
价格走势
公司简介
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro...